Home Tags PD-L1 inhibitor

Tag: PD-L1 inhibitor

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in...

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival (OS) compared to chemotherapy.Globally, approximately...

Avacta and OncoSec Develop Innovative Gene Delivery of Therapeutic Affimers

Avacta Group, the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical, a company developing intratumoral cancer immunotherapies, have entered into a research collaboration...